BOSSION VACHERESSE SORRENTINO MEDICAL : revenue, balance sheet and financial ratios

BOSSION VACHERESSE SORRENTINO MEDICAL is a French company founded 35 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in BONDOUFLE (91070), this company of category PME shows in 2017 a revenue of 3.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - BOSSION VACHERESSE SORRENTINO MEDICAL (SIREN 381717909)
Indicator 2025 2022 2019 2018 2017 2016
Revenue N/C N/C N/C N/C 3 680 737 € 3 258 631 €
Net income 403 208 € 276 597 € 106 608 € -19 833 € 29 126 € 51 633 €
EBITDA N/C N/C N/C N/C 78 453 € 103 825 €
Net margin N/C N/C N/C N/C 0.8% 1.6%

Revenue and income statement

In 2025, BOSSION VACHERESSE SORRENTINO MEDICAL generates positive net income of 403 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 52 k€ -> 403 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

403 208 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 55%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.115%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

54.839%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

20.7%

Solvency indicators evolution
BOSSION VACHERESSE SORRENTINO MEDICAL

Sector positioning

Debt ratio
0.12 2025
2019
2022
2025
Q1: 0.0
Med: 3.67
Q3: 28.55
Good -24 pts over 3 years

In 2025, the debt ratio of BOSSION VACHERESSE SORREN... (0.12) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
54.84% 2025
2019
2022
2025
Q1: 26.28%
Med: 43.48%
Q3: 62.04%
Good -10 pts over 3 years

In 2025, the financial autonomy of BOSSION VACHERESSE SORREN... (54.8%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 183.58. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

183.579

Liquidity indicators evolution
BOSSION VACHERESSE SORRENTINO MEDICAL

Sector positioning

Liquidity ratio
183.58 2025
2019
2022
2025
Q1: 147.44
Med: 215.05
Q3: 310.05
Average -21 pts over 3 years

In 2025, the liquidity ratio of BOSSION VACHERESSE SORREN... (183.58) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
BOSSION VACHERESSE SORRENTINO MEDICAL

Positioning of BOSSION VACHERESSE SORRENTINO MEDICAL in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of BOSSION VACHERESSE SORRENTINO MEDICAL is estimated at 331 241 € (range 126 072€ - 1 209 652€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
124 transactions
126k€ 331k€ 1209k€
331 241 € Range: 126 072€ - 1 209 652€
NAF 5 all-time

Valuation method used

Net Income Multiple
403 208 € × 0.8x = 331 242 €
Range: 126 073€ - 1 209 653€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare BOSSION VACHERESSE SORRENTINO MEDICAL with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about BOSSION VACHERESSE SORRENTINO MEDICAL

What is the revenue of BOSSION VACHERESSE SORRENTINO MEDICAL ?

The revenue of BOSSION VACHERESSE SORRENTINO MEDICAL in 2017 is 3.7 M€.

Is BOSSION VACHERESSE SORRENTINO MEDICAL profitable?

Yes, BOSSION VACHERESSE SORRENTINO MEDICAL generated a net profit of 403 k€ in 2025.

Where is the headquarters of BOSSION VACHERESSE SORRENTINO MEDICAL ?

The headquarters of BOSSION VACHERESSE SORRENTINO MEDICAL is located in BONDOUFLE (91070), in the department Essonne.

Where to find the tax return of BOSSION VACHERESSE SORRENTINO MEDICAL ?

The tax return of BOSSION VACHERESSE SORRENTINO MEDICAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does BOSSION VACHERESSE SORRENTINO MEDICAL operate?

BOSSION VACHERESSE SORRENTINO MEDICAL operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.